- Home
- CAC vs KROS Comparison
CAC vs KROS Comparison
Compare CAC & KROS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CAC
- KROS
- Stock Information
- Founded
- CAC 1875
- KROS 2015
- Country
- CAC United States
- KROS United States
- Employees
- CAC N/A
- KROS N/A
- Industry
- CAC Major Banks
- KROS Biotechnology: Pharmaceutical Preparations
- Sector
- CAC Finance
- KROS Health Care
- Exchange
- CAC Nasdaq
- KROS Nasdaq
- Market Cap
- CAC N/A
- KROS 558.9M
- IPO Year
- CAC 1997
- KROS 2020
- Fundamental
- Price
- CAC $43.17
- KROS $14.68
- Analyst Decision
- CAC Hold
- KROS Buy
- Analyst Count
- CAC 3
- KROS 13
- Target Price
- CAC $47.33
- KROS $20.63
- AVG Volume (30 Days)
- CAC 66.0K
- KROS 487.4K
- Earning Date
- CAC 07-29-2025
- KROS 08-06-2025
- Dividend Yield
- CAC 3.95%
- KROS N/A
- EPS Growth
- CAC 2.54
- KROS N/A
- EPS
- CAC 3.09
- KROS 0.11
- Revenue
- CAC $184,324,000.00
- KROS $214,713,000.00
- Revenue This Year
- CAC $40.83
- KROS $5,006.76
- Revenue Next Year
- CAC $5.29
- KROS N/A
- P/E Ratio
- CAC $13.80
- KROS $132.53
- Revenue Growth
- CAC 13.26
- KROS 91657.70
- 52 Week Low
- CAC $33.83
- KROS $9.12
- 52 Week High
- CAC $50.07
- KROS $72.37
- Technical
- Relative Strength Index (RSI)
- CAC 70.29
- KROS 64.67
- Support Level
- CAC $42.85
- KROS $13.26
- Resistance Level
- CAC $43.78
- KROS $14.68
- Average True Range (ATR)
- CAC 0.98
- KROS 0.41
- MACD
- CAC 0.37
- KROS 0.12
- Stochastic Oscillator
- CAC 95.06
- KROS 89.35
About KROS Keros Therapeutics Inc.
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.